Abbott (ABT) announced the U.S. FDA has approved the company’s Volt PFA System to treat patients battling atrial fibrillation. Abbott will soon begin commercial PFA cases in the United States and will continue its expansion of sites in the European Union following Volt CE Mark approval earlier this year.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott’s Amplatzer Piccolo Delivery System granted FDA and CE clearance
- Abbott Laboratories Expands Board with New Appointment
- Abbott increases quarterly dividend by 6.8% to 63c per share
- 3 Best ETFs to Invest In, According to AI Analyst, 12/09/2025
- Abbott says Lingo CGM now available on Android devices